Published in Crit Rev Oncol Hematol on April 02, 2008
Radiofluorinated rhenium cyclized α-MSH analogues for PET imaging of melanocortin receptor 1. Bioconjug Chem (2010) 0.91
Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells. Transl Oncol (2010) 0.87
Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. Bioconjug Chem (2009) 0.83
Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int J Nanomedicine (2012) 0.82
Improved synthesis and biological evaluation of chelator-modified α-MSH analogs prepared by copper-free click chemistry. Bioorg Med Chem Lett (2011) 0.82
In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma. Cancer Biother Radiopharm (2011) 0.80
166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel. Nucl Med Biol (2013) 0.78
Camptothecin-Loaded Liposomes with α-Melanocyte-Stimulating Hormone Enhance Cytotoxicity Toward and Cellular Uptake by Melanomas: An Application of Nanomedicine on Natural Product. J Tradit Complement Med (2013) 0.78
Evaluation of novel 99mTc(I)-labeled homobivalent α-melanocyte-stimulating hormone analogs for melanocortin-1 receptor targeting. J Biol Inorg Chem (2012) 0.77
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol (2017) 0.75
Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma. Invest New Drugs (2014) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med (2001) 2.32
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys (2001) 2.14
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res (1996) 1.94
99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med (2007) 1.81
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med (2004) 1.76
Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res (2000) 1.73
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med (2005) 1.64
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem (2003) 1.58
A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med (2002) 1.57
[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer (2001) 1.53
Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem (1997) 1.52
Melanoma therapy via peptide-targeted {alpha}-radiation. Clin Cancer Res (2005) 1.52
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep (1984) 1.51
Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem (2005) 1.49
Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med (1999) 1.46
Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol (1999) 1.43
Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med (2007) 1.42
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med (2005) 1.41
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med (2002) 1.40
Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A (1998) 1.39
In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer (2002) 1.37
Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet (1998) 1.34
Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med (2001) 1.33
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med (2002) 1.33
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging (2002) 1.31
Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med (2007) 1.31
Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park) (1995) 1.29
Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A (2004) 1.26
Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem (2000) 1.23
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med (2008) 1.22
Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem (2002) 1.21
Therapeutic radionuclides: production and decay property considerations. J Nucl Med (1991) 1.19
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med (2004) 1.19
Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer (1995) 1.18
Fungal melanins and their interactions with metals. Enzyme Microb Technol (1996) 1.17
Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med (2007) 1.16
The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev (2001) 1.14
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res (1998) 1.13
Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol (2005) 1.12
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med (2006) 1.12
The melanosome: the perfect model for cellular responses to the environment. Pigment Cell Res (2000) 1.12
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med (2002) 1.10
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med (1997) 1.09
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol (2005) 1.08
Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med (2001) 1.07
Efforts to control the errant products of a targeted in vivo generator. Cancer Res (2005) 1.06
Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer (2001) 1.05
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med (1997) 1.04
Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res (2004) 1.04
In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol (1999) 1.03
Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer (2005) 1.02
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm (2007) 1.00
Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol (2001) 0.99
Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm (2006) 0.98
Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res (2005) 0.95
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med (1999) 0.94
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis (2001) 0.93
Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res (1997) 0.93
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res (1998) 0.93
A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med (1993) 0.92
Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol (1997) 0.92
The melanin binding of drugs and its implications. Drug Metab Rev (1984) 0.91
Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol (2000) 0.90
Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem (1997) 0.90
Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med (2000) 0.89
Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res (1992) 0.88
Staging of regional lymph nodes in melanoma patients by means of 99mTc-MIBI scintigraphy. J Nucl Med (2003) 0.86
Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. Bioconjug Chem (1997) 0.86
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol (1996) 0.86
Radionuclide therapy revisited. Eur J Nucl Med (1991) 0.84
Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci (2007) 0.83
Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med (1985) 0.81
Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. J Mol Recognit (2003) 0.80
Biologically active monoiodinated alpha-MSH derivatives for receptor binding studies using human melanoma cells. J Recept Res (1991) 0.80
Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle4, D-Phe7] alpha-MSH in B16 melanoma cells. Int J Biochem Cell Biol (1996) 0.77
Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth alpha radioimmunotherapy. Nucl Med Biol (1996) 0.77
Alpha-melanocyte stimulating hormone message and inhibitory sequences: comparative structure-activity studies on melanocytes. Peptides (1990) 0.77
DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions. Ann N Y Acad Sci (2003) 0.77
Population diversity and the portfolio effect in an exploited species. Nature (2010) 6.88
Biocomplexity and fisheries sustainability. Proc Natl Acad Sci U S A (2003) 5.01
Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res (2003) 1.97
Evidence for geomagnetic imprinting as a homing mechanism in Pacific salmon. Curr Biol (2013) 1.93
99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med (2007) 1.81
Eco-evolutionary vs. habitat contributions to invasion in salmon: experimental evaluation in the wild. Mol Ecol (2007) 1.61
Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem (2003) 1.58
An evaluation of the effects of conservation and fishery enhancement hatcheries on wild populations of salmon. Adv Mar Biol (2007) 1.54
Melanoma therapy via peptide-targeted {alpha}-radiation. Clin Cancer Res (2005) 1.52
Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem (2005) 1.49
111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem (2008) 1.48
Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med (2007) 1.42
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med (2005) 1.41
In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer (2002) 1.37
MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem (2002) 1.28
Copper transport into the secretory pathway is regulated by oxygen in macrophages. J Cell Sci (2009) 1.24
Improved viability of populations with diverse life-history portfolios. Biol Lett (2009) 1.24
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med (2008) 1.22
Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem (2002) 1.21
Reproductive success of captively bred and naturally spawned Chinook salmon colonizing newly accessible habitat. Evol Appl (2012) 1.15
Does variation in selection imposed by bears drive divergence among populations in the size and shape of sockeye salmon? Evolution (2009) 1.12
Predation by bears drives senescence in natural populations of salmon. PLoS One (2007) 1.12
Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol (2005) 1.12
Ten years of varying lake level and selection on size-at-maturity in sockeye salmon. Ecology (2007) 1.08
Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res (2004) 1.04
Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. Clin Exp Metastasis (2003) 1.02
Early marine migration patterns of wild coastal cutthroat trout (Oncorhynchus clarki clarki), steelhead trout (Oncorhynchus mykiss), and their hybrids. PLoS One (2010) 1.02
Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol (2006) 1.01
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm (2007) 1.00
Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin Cancer Res (2007) 0.99
Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol (2007) 0.97
Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem (2002) 0.97
Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection. Clin Cancer Res (2005) 0.93
Melanoma imaging with pretargeted bivalent bacteriophage. J Nucl Med (2007) 0.90
Cycles, stochasticity and density dependence in pink salmon population dynamics. Proc Biol Sci (2010) 0.90
Single nucleotide polymorphisms unravel hierarchical divergence and signatures of selection among Alaskan sockeye salmon (Oncorhynchus nerka) populations. BMC Evol Biol (2011) 0.89
Natural habitat change, commercial fishing, climate, and dispersal interact to restructure an Alaskan fish metacommunity. Oecologia (2009) 0.88
Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol (2009) 0.88
Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer (2010) 0.86
Can interbreeding of wild and artificially propagated animals be prevented by using broodstock selected for a divergent life history? Evol Appl (2012) 0.85
Combinatorial evolution of high-affinity peptides that bind to the Thomsen-Friedenreich carcinoma antigen. J Protein Chem (2003) 0.83
In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Cancer Biother Radiopharm (2010) 0.83
Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci (2007) 0.83
Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH. Nucl Med Biol (2009) 0.83
Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nucl Med Biol (2009) 0.83
Size selectivity of predation by brown bears depends on the density of their sockeye salmon prey. Am Nat (2013) 0.83
Alpha-melanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting. Cancer (2002) 0.82
Thermal heterogeneity mediates the effects of pulsed subsidies across a landscape. Ecology (2010) 0.79
In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles. Mol Imaging Biol (2014) 0.78
Bioinformatic analyses and conceptual synthesis of evidence linking ZNF804A to risk for schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2015) 0.78
Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model. Nucl Med Biol (2010) 0.77
Signals of climate, conspecific density, and watershed features in patterns of homing and dispersal by Pacific salmon. Ecology (2015) 0.77
Microwave-assisted synthesis of HYNIC protected analogue for 99mTc labeled antibody. Curr Radiopharm (2014) 0.76
A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab. Curr Radiopharm (2012) 0.76
(64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen. J Nucl Med (2011) 0.75
Self-sustaining populations, population sinks or aggregates of strays: chum (Oncorhynchus keta) and Chinook salmon (Oncorhynchus tshawytscha) in the Wood River system, Alaska. Mol Ecol (2011) 0.75
The fish and the forest. Sci Am (2006) 0.75
Quantifying and comparing size selectivity among Alaskan sockeye salmon fisheries. Ecol Appl (2012) 0.75
Copper-62 labeled ReCCMSH peptide analogs for melanoma PET imaging. Curr Radiopharm (2012) 0.75